Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody-derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4-1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4-1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-12
DOI
https://doi.org/10.1371/journal.pone.0362221
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones

Koramit Suppipat, Supannikar Tawinwung, Nithidol Sakunrangsit, Trairak Pisitkun et al.
PLoS ONE
CAR-T cell therapy research
article

Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones

Koramit Suppipat, Supannikar Tawinwung, Nithidol Sakunrangsit, Trairak Pisitkun, Sirirut Jewmoung, Chatikorn Boonkrai, Vichaya Chuthaphakdikun, Wipawadee Ruengdej
article en

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody-derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4-1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4-1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.

PLoS ONEVol. 21(11)
Chulalongkorn University (TH), King Chulalongkorn Memorial Hospital (TH)
Chulalongkorn University, Ministry of Public Health, National Research Council of Thailand
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon